摘要目的 观察黑色素瘤缺乏因子2(AIM2)在胰腺癌组织中的表达,并探讨其表达水平与胰腺癌患者临床病理特征及预后的关系.方法 采用免疫组织化学染色法检测94例胰腺癌组织和相应的癌旁组织中AIM2的表达,应用Wilcoxon秩和检验比较胰腺癌及癌旁组织中AIM2表达水平的差异,采用x2检验分析胰腺癌组织中AIM2表达水平与患者临床病理特征的关系,采用Kaplan-Meier生存分析法分析AIM2表达水平与患者总生存期(OS)的关系,拟合Cox模型评价不同指标与患者预后的关系.结果 AIM2在癌旁组织中高表达(226.18 ±59.41),在胰腺癌组织中以低表达为主(195.37 ±63.08),差异有统计学意义(P＜0.01);男性患者AIM2高表达(58.6％)比例低于女性患者(80.6％),差异有统计学意义(x2=4.835,P＜0.05);T1 ～ T2期患者AIM2高表达(73.0％)比例高于T3期患者(45.0％),差异有统计学意义(x2=5.574,P＜0.05);有远处转移患者AIM2高表达比例高于无远处转移患者,差异有统计学意义(P＜0.05).AIM2染色强度与患者其他临床病理特征无明显相关(P＞0.05);Kaplan-Merier生存分析显示,AIM2低表达患者总生存期(OS)较AIM2高表达患者显著缩短,差异有统计学意义[风险比(HR)=1.810,95％可信区间(CI):1.096 ～2.988,P＜0.05].多因素Cox风险比例模型显示,病理分级(HR=0.575,95％CI:0.342～0.964,P＜0.05)和AIM2低表达(HR=1.902,95％CI:1.084～3.338,P＜0.05)均可作为胰腺癌患者预后评判的独立危险因素.结论 AIM2在胰腺癌中呈低表达,有助于胰腺癌患者预后评估.

abstractsObjective To investigate the expression of absent in melanoma 2 (AIM2) in pancreatic cancer tissues and its correlation with patients' clinicopathological characteristics and prognosis.Methods The tissue microarray and immunohistochemistry were used to examine the AIM2 expression in 94 cases of pancreatic cancer tissues and 71 cases of adjacent normal tissues.Wilcoxon rank sum test was used to compare the expression of AIM2 in pancreatic cancer and corresponding adjacent normal tissues.The chi-square test was used to analyze the relationship between the AIM2 expression in pancreatic cancer tissues and clinicopathological features of the patients.Kaplan-Meier survival analysis was performed to analyze the correlation between AIM2 expression and patients' overall survival,and the Cox model was used to analyze the correlation between different clinical parameters and prognosis.Results The immunohistochemistry results showed that AIM2 was highly expressed in adjacent normal tissues (226.18 ±59.41),with no or low expression in pancreatic cancer tissues (195.37 ±63.08),and the difference between cancer tissues and adjacent normal tissues was statistically significant (P ＜ 0.01).The high expression rate of AIM2 in male patients (58.6％) was lower than that in female patients (80.6％,x2 =4.835,P ＜0.05).The high expression rate of AIM2 in patients with T1-T2 (73.0％) was higher than that in patients with T3 (45.0％,x2 =5.574,P ＜ 0.05).The proportion of AIM2 high expression in patients with distant metastasis was higher than that in patients without distant metastasis (P ＜ 0.05).The intensity of AIM2 staining was not significantly correlated with other clinicopathological features (P ＞ 0.05).Kaplan-Merier survival analysis showed that the overall survival (OS) of patients with low expression of AIM2 was significantly shorter than that of patients with high AIM2 expression [hazard ratio (HR) =1.810,95％ confidence interval (CI):1.096-2.988,P ＜ 0.05].Multi-factor Cox model analysis indicated that pathological grade (HR =0.575,95％ CI:0.342-0.964,P ＜ 0.05) and AIM2 high expression (HR =1.902,95％ CI:1.084-3.338,P ＜0.05) were independent prognostic factors of pancreatic cancer patients.Conclusion AIM2 is expressed lowly in pancreatic cancer and can be used as a major factor in the prognosis evaluation of pancreatic cancer patients.